Internal Medicine, Hematology & Oncology · Fayetteville, GA
NPI
1013295922
Since 2011
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
1267 Highway 54 W Ste 4200
Fayetteville, GA, 30214
Phone (678) 829-1060
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.4M
215,089 services
Medicare patients, 2024
539
Average age 75
Drug cost, 2024
$10.1M
4,026 prescriptions
Company payments, 2025
$1,691
From 38 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vipin Ramprasad Lohiya was code J9271 (injection, pembrolizumab, 1 mg), 32,800 times for 24 patients. In total Vipin Ramprasad Lohiya billed 215,089 services in 142 codes, and Medicare paid $4.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-05-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 32,800 | 24 | $42.40 | $1.4M |
| J1442 Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Office | 30,000 | 15 | $0.73 | $22K |
| J0897 Injection, denosumab, 1 mg | Office | 14,220 | 46 | $19.54 | $278K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 13,500 | 12 | $0.05 | $716 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 5,700 | 46 | $14.91 | $85K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,532 | 48 | $0.09 | $217 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 1,609 | 15 | $3.41 | $5,487 |
| 85025 Blood Count | Office | 1,299 | 395 | $7.57 | $9,833 |
| J9190 Injection, fluorouracil, 500 mg | Office | 1,175 | 17 | $2.26 | $2,650 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 730 | 19 | $0.70 | $513 |
| 99214 Office E&M - Established | Office | 620 | 183 | $89.85 | $56K |
| 96413 Chemotherapy Administration | Office | 525 | 82 | $92.50 | $49K |
| 96372 Injection Administration | Office | 510 | 124 | $10.20 | $5,201 |
| 96367 Intravenous Infusion, Hydration | Office | 470 | 56 | $20.29 | $9,538 |
| J9045 Injection, carboplatin, 50 mg | Office | 430 | 18 | $2.66 | $1,142 |
By year: 2022 $3.9M for 205,131 services; 2023 $5.0M for 251,946 services; 2024 $4.4M for 215,089 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,299 | 395 | $7.57 | $9,833 |
| 81002 Clinical Chemistry | 48 | 19 | $3.41 | $164 |
Medicare prescription drug claims, 2024
In 2024, the drug Vipin Ramprasad Lohiya prescribed most often to Medicare patients was Eliquis (Apixaban), with 211 prescriptions and refills. In total Vipin Ramprasad Lohiya wrote 4,026 Medicare prescriptions that cost $10.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 211 | 282 | 51 | $162K |
| Anastrozole Generic | 207 | 497 | 57 | $3,317 |
| Revlimid Lenalidomide | 160 | 160 | 18 | $2.5M |
| Pantoprazole Sodium Generic | 149 | 263 | 59 | $798 |
| Valacyclovir Valacyclovir Hcl | 130 | 213 | 39 | $4,018 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 130 | 130 | 72 | $1,614 |
| Dexamethasone Generic | 127 | 140 | 72 | $2,793 |
| Ondansetron Odt Ondansetron | 126 | 127 | 85 | $2,956 |
| Tamoxifen Citrate Generic | 123 | 292 | 37 | $2,703 |
| Potassium Chloride Generic | 120 | 180 | 40 | $5,244 |
| Prochlorperazine Maleate Generic | 114 | 116 | 86 | $1,838 |
| Verzenio Abemaciclib | 108 | 108 | 14 | $1.6M |
| Gabapentin Generic | 102 | 139 | 33 | $1,196 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 93 | 93 | 38 | $2,300 |
| Mirtazapine Generic | 84 | 114 | 21 | $993 |
Brand drugs: 1,117 claims; generic drugs: 2,909 claims; opioid claims: 290.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vipin Ramprasad Lohiya $1,691 ($1,691 in general payments such as food, travel and fees) from 38 companies. The largest payer was Gilead Sciences, Inc. with $204.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 4 | $204 |
| Pfizer Inc. PFE | 8 | $138 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $120 |
| Abbvie Inc. ABBV | 5 | $109 |
| Merck Sharp & Dohme LLC MRK | 4 | $99.1 |
| Eisai Inc. 4523.T | 5 | $88.16 |
| Seagen Inc. PFE | 1 | $74.99 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $63.1 |
| Janssen Biotech, Inc. JNJ | 2 | $52.01 |
| Daiichi Sankyo Inc. 4568.T | 2 | $47.24 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.